TARS Stock Analysis: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$56.11
-3.20 (-5.40%)
▼
5d:
-20.47%
30d:
-10.38%
90d:
-22.77%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
20d
Smart Money Distribution
None View Scanner →
Strength: 6.6/10
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called TARS this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TARS is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TARS is down 20.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$94.58
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$58.73
4.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $56.11, which is considered oversold relative to its 30-day fair value range of $59.61 to $65.95. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.8) compared to its historical average (35.6). Remarkably, the market is currently pricing in an annual earnings decline of 16.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is in a downtrend. The price is currently testing key support at $55.53. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $94.25 (+68.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARS is in a downtrend. The price is currently testing key support at $55.53. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $94.25 (+68.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$59.61 -
$65.95
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding TARS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 68.0% below Wall St target ($94.25)
- WARNING: Recommendation downgraded due to -20.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$59.61 -
$65.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$55.53
Resistance Level
$72.50
Current Trend
Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.78
Wall Street Target
$94.25
(+68.0%)
Revenue Growth (YoY)
106.9%
Profit Margin
-9.0%
Valuation Discount vs History
-16.4% cheaper
PE vs Historical
20.8 vs 35.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.4%
(market-implied from PE analysis)
1-Year Target
$50.50
(-10%)
2-Year Target
$45.45
(-19%)
3-Year Target
$40.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 21→36)
$70.07
(+25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.8 to 35.6
Stabilization Target:
$96.12
(+71.3%)
PE Expansion Potential:
+71.3%
Share & Embed Analysis
Last updated: July 14, 2026 9:11 PM ET
Data refreshes hourly during market hours. Next update: 10:11 PM
Data refreshes hourly during market hours. Next update: 10:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
Bryan Wahl
SELL
4231 shares
2026-03-19
Dianne C Whitfield
SELL
4174 shares
2026-03-19
Elizabeth Yeu Lin
SELL
390 shares
2026-03-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
